DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
| You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
| To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Debate Over Universal Screening for Thyroid Dysfunction in Pregnancy Centers on What to Treat
The question about screening for thyroid dysfunction during pregnancy remains one with no clear answer, according to a debate at the Endocrine Society Annual Meeting.
Determining whether screening for any condition — including thyroid dysfunction — should be recommended is based on criteria established by the WHO, which calls for a common condition, an available and reliable screening tool, proof of favorable influences of intervention, relative cost-effectiveness and a uniform policy.
Experts mostly agree that thyroid dysfunction in pregnancy is common. Alex Stagnaro-Green, MD, MHPE, MHA, of the University of Illinois College of Medicine in Rockford, who argued for universal screening during the debate, noted that in searching the current literature, the ranges for prevalence were up to 13.1% for overt hypothyroidism and up to 2.5% for overt hyperthyroidism.
myBinderRelated Content
-
News & MeetingsASOPRS 2023 Fall Scientific SymposiumThe American Society of Ophthalmic Pla...
-
Evidence & EducationGraves’ Disease After Treatment With Alemtuzumab for Multiple SclerosisContext: Alemtuzumab, a humanized monoc...
-
Evidence & EducationA Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine PracticeObjective: There are scarce reports reg...
-
People & PlacesKevin Thomas Brumund, MDKevin Brumund is Associate Professor in ...
-
Evidence & EducationProspective, Systematically Recorded Mycophenolate Safety Data in Graves’ OrbitopathyContext: The antiproliferative mechanis...
-
Evidence & EducationGraves’ Disease and PregnancyHypothyroidism During Pregnancy At firs...
-
Evidence & EducationPreoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.